QCG
CGEM icon

Quadrant Capital Group’s Cullinan Oncology CGEM Stock Holding History

Quadrant Capital Group’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-761
Closed -$10.8K – 1489
2026
Q1 		$10.8K Hold
761
– – ﹤0.01% 2173
2025
Q4 		$7.88K Sell
761
-143
-16% -$1.29K ﹤0.01% 2265
2025
Q3 		$5.36K Buy
+904
New +$6.62K ﹤0.01% 2309
2025
Q2 		– Sell
-2,972
Closed -$22.5K – 1580
2025
Q1 		$22.5K Buy
2,972
+2,731
+1,133% +$26.2K ﹤0.01% 2003
2024
Q4 		$2.94K Sell
241
-20
-8% -$287 ﹤0.01% 2442
2024
Q3 		$4.37K Sell
261
-27
-9% -$479 ﹤0.01% 2349
2024
Q2 		$5.02K Sell
288
-18
-6% -$383 ﹤0.01% 2287
2024
Q1 		$5.21K Buy
306
+65
+27% +$1K ﹤0.01% 2303
2023
Q4 		$2.46K Buy
+241
New +$2.13K ﹤0.01% 2436
2023
Q1 		– Sell
-631
Closed -$6.66K – 2728
2022
Q4 		$6.66K Buy
+631
New +$7.67K ﹤0.01% 2126

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Quadrant Capital Group's CGEM Position: Q2 2026 in Review

Quadrant Capital Group sold out of Cullinan Oncology (CGEM) in Q2 2026, closing a stake of 761 shares — an estimated $10.8K sold.

Quadrant Capital Group first reported a position in CGEM in Q4 2022 and held it in 10 quarters. The position peaked at $22.5K in Q1 2025. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Quadrant Capital Group reported no remaining Cullinan Oncology position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 761 Cullinan Oncology shares in Q2 2026, an estimated $10.8K.
  • Quadrant Capital Group first reported a position in Cullinan Oncology in Q4 2022 and held it in 10 quarters.
  • Quadrant Capital Group's Cullinan Oncology position peaked at $22.5K in Q1 2025.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.